EXHIBIT 10.12

                                  [CyGene LOGO]

                              CONSULTING AGREEMENT

Agreement, dated as of 12-08-2005, between Dx Innovations, Inc. (3935 Lago di
Grata Cir., San Diego, CA 92130; hereafter Dx Innovations) and CyGene, Inc.
(hereinafter CyGene), having principal place of business at:

                  7786 Wiles Road
                  Coral Springs, FL 33067

CyGene, Inc. desires to retain the services of Dx Innovations in a consulting
capacity with respect to certain activities as described in Exhibit A, and Dx
Innovations is willing to so act.

NOW, THEREFORE, Dx Innovations and CyGene agree as follows:

1.   Description of Services. CyGene hereby retains Dx Innovations as to perform
     the following services for CyGene:

     a)  An estimated 40 hours per month consultation with CyGene's scientist or
         management or as otherwise designated by CyGene, in the form of formal
         meetings or consultation.

     b)  Dx Innovations may from time to time be unavailable to attend formal
         meetings or perform other consulting duties that are not in conflict
         with or competitive to the business activities of CyGene, and such
         unavailability shall not be considered a breach of this AGREEMENT.

     c)  Dx Innovations' consultation will involve the specialized field of
         molecular biology and requires the application of the unique, special
         and extraordinary skills and knowledge that Dx Innovations possesses in
         this area.

2.   Term and Expiration. This Agreement shall become effective as of the date
     hereof and remain in effect for six (6) months. In rendering services to
     CyGene, Dx Innovations shall act as an independent contractor and not as an
     employee or agent of CyGene.

3.   Compensation. For all services provided hereunder, CyGene will pay Dx
     Innovations a fee of $250 per hour. Payment will be made in cash and CyGene
     common stock as outlined in Exhibit B. Payments will be made in arrears, on
     a weekly billing basis or as otherwise agreed upon by both parties.

4.   Expenses. CyGene will reimburse Dx Innovations for any actual expenses
     incurred by Dx Innovations while rendering services under this Agreement so
     long as the expenses are reasonable and necessary, upon prior written
     approval by CyGene. Such expenses shall include reasonable and necessary
     travel, lodging and meals in connection with services performed under this
     Agreement. Requests for reimbursement shall be in a form reasonably
     acceptable to CyGene.

                                   Page 1 of 5
                                               Dx Innovations - CyGene Agreement


<PAGE>
                                  [CyGene LOGO]

5.   Proprietary Information and Patents. Dx Innovations understands and agrees
     that CyGene possesses and will continue to possess information that has
     been created, discovered, or developed, or has otherwise become known to
     CyGene, including information made known to or created, discovered, or
     developed by Dx Innovations, arising out of its retention as a consulting
     firm by CyGene, which information has commercial value in the business in
     which CyGene is engaged. All of the aforementioned information is
     hereinafter called "Proprietary Information." By way of illustration, but
     not limitation, Proprietary Information includes trade secrets, processes,
     formulae, data and know-how, improvements, inventions, techniques, planned
     products, research and development, marketing plans, business plans,
     strategies, forecasts, customer lists, confidential information about
     finances, marketing, pricing, costs or compensation.

              a)  All Proprietary Information shall be the sole property of
                  CyGene and its assigns, and CyGene and its assigns shall be
                  the sole owner of all patents and other rights in connection
                  therewith. At all times during its retention as a consulting
                  firm for CyGene and at all times after termination of such
                  retention as a consulting firm, Dx Innovations will keep in
                  confidence and trust all Proprietary Information, and will not
                  use for its own account (or for the benefit of any person or
                  entity), or disclose any Proprietary Information or anything
                  relating to it without the written consent of CyGene, except
                  as may be necessary in the ordinary course of performing its
                  duties as a consultant of CyGene.

              b)  All documents, data, records, apparatus, equipment and other
                  physical property, whether or not pertaining to Proprietary
                  Information, furnished to Dx Innovations by CyGene or produced
                  by Dx Innovations or others in connection with Dx Innovations'
                  retention shall be and remain the sole property of CyGene and
                  shall be returned promptly to CyGene as and when requested by
                  CyGene. Should CyGene not so request, Dx Innovations shall
                  return and deliver all such property upon termination of its
                  retention as a consulting firm for any reason, and Dx
                  Innovations will not retain any such property or reproduction
                  of such property upon such termination.

              c)  Subject to the provisions of Article 7. Dx Innovations will
                  promptly disclose and assign to CyGene, or any persons
                  designated by it, all improvements, inventions, formulae,
                  processes, techniques, know-how and data, whether or not
                  patentable, (collectively hereinafter called "INVENTIONS")
                  made or conceived or reduced to practice by Dx Innovations,
                  either alone or jointly with others, during the period of its
                  retention as a consultant which (i) result from tasks assigned
                  to Dx Innovations by CyGene, or (ii) result from use of
                  premises owned, leased or contracted for by CyGene All
                  INVENTIONS shall be the sole property of CyGene and its
                  assigns, including all patents and other proprietary rights in
                  connection therewith. Dx Innovations agrees to execute all
                  documents and take all actions necessary to assign and
                  transfer the foregoing to CyGene.

              d)  Dx Innovations' scientists may freely publish any results of
                  its work covered under the Agreement, provided that prior U.S.
                  patent application is made on any potentially patentable
                  aspects of its work. Dx Innovations agrees to provide CyGene
                  with sufficient disclosure not less than 120 days prior to
                  publication, to allow CyGene to have patent applications
                  prepared on inventions or other information made or acquired


                                   Page 2 of 5
                                               Dx Innovations - CyGene Agreement

<PAGE>
                                  [CyGene LOGO]

                  under this agreement of potential commercial value. CyGene
                  agrees to keep all such disclosures confidential prior to
                  publication.

              e)  Nothing in this Agreement shall transfer to CyGene any rights
                  to INVENTIONS that are owned or are provided to Dx Innovations
                  by third parties for research purposes.

6.   Governing Law. This Agreement shall be governed and construed in accordance
     with the laws of the State of Florida.

7.   No Conflict. Dx Innovations represents that its performance of all the
     terms of this Agreement and that its retention as an advising firm to
     CyGene does not and will not breach any agreement to keep in confidence
     proprietary information acquired by Dx Innovations in confidence or in
     trust prior to its retention as an advising firm by CyGene Dx Innovations
     has not entered into, and agrees he will not enter into, any agreement,
     either written or oral, in conflict herewith. Dx Innovations understands as
     part of the consideration for the offer to retain it as an advising firm,
     and of its retention as an advising firm by CyGene, that it has not brought
     and will not bring to CyGene or use in the performance of its
     responsibility at CyGene any equipment, supplies, facility or trade secret
     information of any current or former clients which are not generally
     available to the public, unless Dx Innovations has obtained written
     authorization for their possession and use. Dx Innovations also understands
     that, in its retention as an advising firm of CyGene, it is not to breach
     any obligation of confidentiality that it has to others, and it agrees that
     it shall fulfill all obligations during its retention as an advising firm
     with CyGene.

8.   Successors, etc. This Agreement shall be binding upon and shall inure to
     the benefit of CyGene's successors, transferees, and assigns.

9.   This agreement can be terminated by either party within 30 days written
     notice.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
day and year written below.

   For CYGENE, INC.:

   ______________________________                    __________________
   Martin Munzer, President & CEO                         Date

   For DX INNOVATIONS, INC.:

   ________________________________                  __________________
   Andreas Braun PhD, MD, President                       Date


                                   Page 3 of 5
                                               Dx Innovations - CyGene Agreement

<PAGE>
                                  [CyGene LOGO]

                                    Exhibit A

CyGene, Inc. engages Dx Innovations, Inc as a consulting firm to:

1)     Review and edit current and future testing result report forms for
       CyGene's direct to consumer DNA testing business
2)     suggest improvements of testing panels and report generating algorithms
3)     translate report forms into German for test results report generation and
       marketing of CyGene's test panels in Germany and Europe
4)     assist CyGene in its business and product development efforts
5)     advise and assist in ongoing and future Haystack Processing technology
       developments.

CyGene will provide literature that was central for developing report
algorithms.


                                   Page 4 of 5
                                               Dx Innovations - CyGene Agreement

<PAGE>
                                  [CyGene LOGO]

                                    Exhibit B

Payment schedule: 25% of billed invoice shall be paid in cash and the remaining
75% are payable in restricted shares of common stock at a 50% discount from the
market price based on the ten day prior closing average of CYGE stock, when the
invoice is presented. There is a $0.25 minimum price to any issuances of stock.


                                   Page 5 of 5
                                               Dx Innovations - CyGene Agreement